May 17, 2020

Health startup QMedic awarded $2.2 million from National Cancer Institute

Admin
2 min
Health startup QMedic awarded $2.2 million from National Cancer Institute.jpg
QMedic, a leader in themobilehealth market, has been awarded$2.2 Million from the National Cancer Institute (NCI) to createnext-generation passive sens...

QMedic, a leader in the mobile health market, has been awarded $2.2 Million from the National Cancer Institute (NCI) to create next-generation passive sensing and self-report tools to enhance clinical interventions for at-risk patients.  At the core of this initiative, QMedic is launching a 3-year clinical partnership with Northwestern University's Robert H. Lurie Comprehensive Cancer Center (RHLCCC) and the Rehabilitation Institute of Chicago (RIC), which will focus on delivering mHealth interventions to cancer rehabilitation patients based in remote environments.   

"To this point, passive sensing has been limited to 'quantified self' applications, which appeal to the fitness enthusiast but offer little to no insight to clinicians interested in shifting the paradigm of care delivery from treatment to prevention," said QMedic CEO Sombit Mishra.   "Our partnership with Northwestern and the National Cancer Institute is designed to validate and scale an integrated mHealth approach for measuring and improving patient outcomes in the home." 

US News & World Report has ranked Northwestern's RHLCCC-RIC as the #1 physical medicine and rehabilitation center in the country 23 years in a row.  Says Dr. Samman Shahpar, Medical Director of RHLCCC-RIC, "The mHealth tools that QMedic is developing could significantly improve the quality of care by enabling us to identify early on which patients are good candidates for cancer rehabilitation services."

According to Dr. Lynne Wagner, Associate Professor at Northwestern University Feinberg School of Medicine and Director of the RHLCCC Survivorship Program, "early identification of cancer survivors for medical evaluation and cancer rehabilitation services optimizes outcomes, particularly among older adults at risk for functional declines."

Since 2011, QMedic has generated close to $2.5 million in funding from the NCI.  The current round of contracts includes approximately $1 Million for Contract No. HHSN261201300082C and $1.2 Million for Contract No. HHSN261201300055C.  These Small Business Innovation Research (SBIR) contracts have been funded in whole with Federal funds from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services.


Read more about Mobile health startup QMedic awarded $2.2 Million from National Cancer Institute, launches 3-year clinical partnership with Northwestern University Hospital - BWWGeeksWorld by www.broadwayworld.com

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article